Ann: Mesoblast Update on Chronic Low Back Pain Program, page-348

Oh, here we go again with your conspiracy theories. You’re quoting an update from 2021 and acting like it’s some grand revelation. Let me clear this up for you:

Mesoblast has been working through a complex regulatory environment for years, and anyone with basic knowledge of biotech knows the FDA doesn’t hand out approvals like candy. The shift in strategy you’re ranting about isn’t some betrayal—it’s a smart move to ensure they hit the milestones needed for success.

You’re losing your mind over Mesoblast doing a P3 on their own? It’s called adapting to the situation, something you apparently don’t understand. The fact that they’re working with the FDA to figure out the most efficient path forward is actually a positive. They’re adjusting based on feedback, which is literally how the approval process works. But instead, you’re acting like this is a plot against shareholders. You talk about a ‘track record of 0 from 4’—as if setbacks are unheard of in biotech. Another Newsflash: most companies in this space face multiple trials and adjustments before they hit their stride.

And now you’re losing it over the payment from Grünenthal? It’s been clearly stated that future payments are contingent on regulatory approvals and milestones being met—standard contract terms in partnerships like this. Nothing shady, nothing out of the ordinary, but of course, you’re twisting it into some paranoid fantasy where only ‘special SHs’ like GG know the truth. GG’s making his moves based on the same info everyone else has, but you’re over here building a conspiracy web out of thin air.

Let’s not even start on your ‘I think I need to see a psychiatrist’ line. You might be joking, but you’re dead on—this level of speculation, without any evidence, sounds more like paranoia than investing. You’ve been spinning these theories for how long now? And where’s it gotten you? You’re not providing clarity, you’re just fuelling your own delusions.

So let’s cut the crap. Mesoblast is navigating a tough market, and yes, they’ve faced challenges. But the idea that there’s some grand subterfuge going on, and only you’ve figured it out, is laughable. If you’re so upset about them adapting to survive, then maybe biotech investing isn’t for you. You’re not exposing anything new; you’re just rehashing the same tired, paranoid nonsense.